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Abstract
Objective—This study evaluated demographic and clinical correlates and predictors of
polypharmacy at baseline assessment in the Longitudinal Assessment of Manic Symptoms
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(LAMS) sample, a cohort of children age six to 12 years at their first outpatient mental health visit
at university-affiliated clinics.
Methods—Use of medications in four classes (mood stabilizers, antidepressants, antipsychotics,
and stimulants) was assessed, and the Service Assessment for Children and Adolescents classified
lifetime and current use of various services. Analyses examined correlates of the number of
medications prescribed and odds of polypharmacy, defined as use of two or more concurrent
medications.
Results—In the total sample, 201 of 698 participants (29%) were prescribed two or more
medications. These participants had lower Children's Global Assessment Scale scores, more
comorbid disorders, and higher baseline parent-reported mood symptoms than those prescribed no
or one medication. White youths were three times as likely as nonwhite youths to be receiving two
or more psychotropics, even after adjustment for other demographic and clinical characteristics.
Of 262 participants (38% of sample) not being treated with medications, 252 (96%) had a
diagnosis of at least one psychiatric disorder (74% had two or more).
Conclusions—Findings suggest that patients with greater severity and comorbidity were more
likely to receive two or more medications. However, 38% of these children with serious disorders
were not receiving psychotropic medication at the time of this assessment. Results counter
findings suggesting overtreatment with medications of children with psychiatric disorders in the
community.
The Longitudinal Assessment of Manic Symptoms (LAMS), funded by the National
Institute of Mental Health, was designed to follow prospectively an epidemio-logically
ascertained cohort of children with elevated symptoms of mania receiving outpatient care, as
well as a comparison group of children without such symptoms also receiving out-patient
care. The study was designed both to delineate the relationship between manic symptoms
and bipolar disorder and to carefully define the characteristics of children with elevated
symptoms of mania. Children with mood and behavior disorders, such as those experienced
by children in the LAMS sample, are frequently treated with one or more psychotropic
medications (1), but there is also evidence that many youths with diagnosable psychiatric
disorders receive no treatment (2).
The pediatric use of psychotropic medications has been criticized in the media (3) and
scientific literature (4,5). Critics have cited a lack of substantive evidence as to their
efficacy, effectiveness, and safety for children and adolescents. However, most previous
studies have analyzed claims data and have not included thorough assessments of diagnosis,
service utilization, comorbid disorders, and other important clinical factors, such as
functioning. Constantine and colleagues (6) analyzed data from a Florida Medicaid database
and found that 7% of children and 8% of adolescents had at least one episode of receiving
two or more psychiatric medications during the five-year period (July 2002 to June 2007).
They reported that the following factors increased the odds of receiving two or more
psychiatric medications: being an adolescent (odds ratio [OR]=1.16), race indicated as
“other” (OR=1.18), and presence of psychosis (OR=1.47). Zito and colleagues (4) reviewed
Texas Medicaid data for a July 2004 random sample of 472 medicated youths in foster care
age 0 through 19 years. In this sample, the average number of psychiatric medications
received by each child was 2.55, and 41% received three or more classes of psychotropic
medications.
LAMS used an epidemiological approach to assemble a cohort of children age six to 12
years at their first out-patient mental health visit at university-affiliated clinics (7). Initial
results have confirmed the finding that elevated symptoms of mania in mental health settings
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are in fact common and that most children with such symptoms meet DSM-IV criteria for a
variety of disorders other than a bipolar spectrum disorder at baseline (1).
The LAMS sample was thoroughly assessed at baseline with state-of-theart research
instruments for primary psychiatric disorders, comorbid disorders, level of functioning, and
medication use. It is important to understand that LAMS is a longitudinal observational
study and not a treatment study. LAMS participants were screened and recruited during their
first mental health visit at clinics associated with four academic medical centers in the
Midwest. Most LAMS participants were treated in their local community, and in most cases
the LAMS team clinicians provided no feedback about diagnosis or treatment provided to
the child's prescribing clinician. Thus these results reflect community practices rather than a
controlled trial. This combination of a naturalistic epidemiological design with research-
grade description of diagnoses and service utilization offers a crucial window into the debate
about current clinical patterns of prescription.
The purpose of this analysis was to use the LAMS cohort to examine factors associated with
polypharmacy in the outpatient treatment of youths referred because of emotional and
behavioral concerns. We examined bivariate relationships between demographic and clinical
characteristics and the number of medications the youth was taking concurrently.
Hierarchical logistic regression analyses quantified the extent to which sets of demographic
and clinical characteristics contributed to the odds of polypharmacy. We also tested whether
any factors demonstrated unique incremental effects. We hypothesized that diagnosis and
severity would significantly increase the odds of polypharmacy. Because polypharmacy
carries increased risk of side effects, adverse events, and fiscal costs, we approached the
analyses as an investigation of potential harm. Thus we did not use a post hoc correction,
which would have reduced power to detect potentially important predictors of
polypharmacy. For example, if a variable was associated with polypharmacy with an
uncorrected p value of .04, post hoc correction would reclassify it as non-significant,
whereas not using a post hoc correction would flag the variable for discussion.
Methods
Study sites and participant ascertainment
All study procedures were reviewed and approved by the institutional review boards at each
of the four university-affiliated sites where LAMS is being conducted. Written informed
consent from parents or guardians and assent from youths were obtained before any study-
related procedures were performed.
The LAMS source population consisted of all children between the ages of six and12 years
and 11 months who were making a first visit to nine child outpatient clinics associated with
the four university-affiliated medical centers in the LAMS study. Parents or guardians
accompanying eligible children were approached by researchers using procedures approved
by the institutional review board at each university or hospital. Recruitment occurred
between December 13, 2005, and December 18, 2008. After providing consent to
participate, adults were asked to complete the ten-item Parent-Completed General Behavior
Inventory Mania Form (P-GBI-10M) (8) and to answer questions about sociodemographic
characteristics.
Of 3,329 families who were approached at the participating clinics, 2,622 (79%) agreed to
screening. Nearly half (N=1,124, 43%) scored above the a priori cutoff of 12 on the P-
GBI-10M, indicating that the child had elevated symptoms of mania. The threshold of 12
was deliberately set low, both to increase sensitivity to bipolar spectrum disorders and to
include a wide variety of cases not meeting criteria for bipolar disorder in order to
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investigate the course of cases that might have some features similar to those of mood
disorders. Of the 1,124 children, 1,111 were eligible for the longitudinal follow-up portion
of the study; 13 were ineligible because the parent reported a diagnosis of autism or an IQ of
less than 70. Of the 1,111 eligible children with elevated symptoms of mania, 621 parent-
child dyads (56%) agreed to participate.
For every ten children with elevated symptoms of mania, one child without such symptoms
(score below 12 on the P-GBI-10M) was selected as a potential comparator. A total of 86
parent-child dyads in which the child was negative for elevated symptoms of mania agreed
to participate, resulting in an overall sample of 707 children and their parents. Information
on the study design, sample selection, and children's sociodemographic characteristics has
been previously reported (7). Rates of attention-deficit hyperactivity disorder (ADHD),
anxiety disorders, psychosis, elimination disorders, and depression were similar between the
86 children without elevated symptoms of mania and the 621 children who met criteria for
such symptoms at screening, but the former group had significantly lower rates of bipolar
disorders (N=7, 8%) and disruptive behavior disorders (N=30, 35%). Families who agreed
to participate in the longitudinal portion of the study were scheduled for a baseline
interview, which has been described in detail elsewhere (1).
Measures
Demographic characteristics—Parents or guardians provided demographic
information, including child age, sex, race, ethnicity, and health insurance status, as well as
information on family composition, socioeconomic status, parental education and
employment, and medical history.
Psychiatric diagnoses—To assess for current and past psychiatric disorders, children
and their parent or guardian were administered the Schedule for Affective Disorders and
Schizophrenia for School-Age Children–Present and Lifetime Version (9) (K-SADSPL),
with additional items about depression and manic symptoms derived from the Washington
University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (10).
Items screening for DSM-IV criteria for pervasive developmental disorders were also added
to the K-SADS-PL. The resulting instrument, the K-SADSPL-W, is a semistructured
interview that assesses current and lifetime psychiatric diagnoses and the time course of
each illness. The presence or absence of mood disorder diagnoses was assessed at the
baseline evaluation and every six months thereafter. The entire K-SADSPL-W was repeated
annually.
Unmodified DSM-IV diagnostic criteria were used in the LAMS study. The criteria for
bipolar disorder not otherwise specified were clarified for the LAMS study to follow the
same criteria used in the Course and Outcome of Bipolar Youth study (11). Bipolar disorder
not otherwise specified was operationalized as follows: elated mood plus two associated
symptoms of mania (for example, grandiosity, decreased need for sleep, pressured speech,
racing thoughts, and increased goal-directed activity) or irritable mood plus three associated
symptoms of mania; change in level of functioning; presence of symptoms for a total of at
least four hours within a 24-hour period; and at least four episodes of four hours’ duration or
a total of four days of the above-noted symptom intensity in the child's lifetime. All
diagnoses were reviewed and confirmed by a licensed child psychiatrist or psychologist.
For the analyses reported here, eight summary variables indicated whether the youth had a
diagnosis of ADHD, bipolar spectrum disorders, depression or dysthymia, anxiety disorders,
disruptive behavior disorder (oppositional defiant disorder or conduct disorder), elimination
disorders, pervasive developmental disorder, or a history of psychosis (including psychosis
during mood episodes as well as schizophrenia). We treated psychosis as a separate variable
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because it might separately predict polypharmacy above and beyond the main effects of
bipolar or depressive disorders.
Functional assessment—Study interviewers completed the Children's Global
Assessment Scale (CGAS) to provide a severity rating of participants’ current impairment,
measuring overall functional capacity at home, at school, and with peers (12).
Symptomatic assessment—In addition to administration of the K-SADSPL-W, which
ascertained presence or absence of manic and depressive symptoms specifically within the
context of a mood episode (that is, “filtered” ratings), “unfiltered” ratings of apparent mood
symptoms regardless of whether they occurred within the context of a mood episode were
also assessed via both parental self-report and clinical rating. Manic and behavioral
dysregulation symptoms, regardless of etiology, were assessed by parent report with the P-
GBI-10M as well as with the Young Mania Rating Scale (YMRS) (13), which was
administered to both the parent and child. The P-GBI-10M and YMRS scores were
correlated (r=.43, p<.001). Similarly, the presence and severity of depressive symptoms,
regardless of etiology, were assessed with the Children's Depression Rating Scale–Revised
(CDRS-R) (14). Parent-reported scores on the ADHD, oppositional defiant disorder, and
conduct disorder sub-scales were examined with the Child and Adolescent Symptom
Inventory 4R–Parent Version (15). Finally, the total score on the four-item outward
irritability subscale of the Irritability, Depression, Anxiety Scale (16) was used to measure
irritability.
Family factors—The Family History Screen (17) was administered at the baseline
assessment to collect information on 15 psychiatric disorders and suicidal behavior of
biological parents and of first- and second-degree relatives. The analyses reported here
concentrated on two summary variables capturing whether the mother or father had a history
of a mood disorder or cognate diagnoses potentially associated with a familial history of
mood disorder, such as schizophrenia, antisocial personality disorder, or substance abuse or
dependence (18). Thirty-two percent (N=224) of children lived with both biological parents.
Mental health services use—The parent version of the Service Assessment for Children
and Adolescents (SACA) (19,20) was used to gather information about the child's lifetime
and current use of various mental health services in three broad domains: inpatient,
outpatient, and school. Parents or guardians were asked to rate how well the most recent
outpatient services matched their child's needs and how much their child had benefited from
the most recent treatment.
Medication history—As part of the SACA, each child's parent or guardian provided a
complete history of the child's past and currently prescribed psychotropic medications.
Medications were grouped according to class (mood stabilizers, antidepressants,
antipsychotics, stimulants, and “other”). For simplicity, lithium and anticonvulsants were
classified as mood stabilizers. Current medication use was quantified in several ways: the
number of medications taken simultaneously, a dummy code indicating whether the person
was receiving two or more medications concurrently, and dummy codes for inclusion in
regression models indicating whether the youth was taking an antipsychotic, a stimulant, an
anti-depressant, or a mood stabilizer.
Statistical analyses
Data were double-entered using SPSS Data Builder/Entry, version 3. Statistical analyses
were conducted with SAS, version 9.2, and SPSS, version 19. Descriptive statistics included
examination of skewness and kurtosis. Chi square analyses tested associations between
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levels of medication use and categorical variables, and one-way analyses of variance tested
bivariate associations with continuous measures. This framework allowed for potential
nonlinear effects for medication augmentation.
Polypharmacy was operationally defined as taking two or more psychiatric medications
concurrently. It served as the dependent variable in logistic regression models testing the
predictors in hierarchically organized blocks. As a sensitivity analysis, the number of
concomitant medications was the dependent variable in a set of Poisson regressions to
evaluate whether the predictors of number of medications were similar to the predictors of
polypharmacy. All hypothesis tests were considered statistically significant if the p value
was <.05. We elected not to use a more conservative alpha level because we were
specifically interested in predictors of higher medication usage, and thus more stringent
alpha levels might prevent detection of important predictors of polypharmacy (21). Post hoc
error correction would make it more difficult to detect predictors of poly-pharmacy. The
study was designed to provide adequate statistical power for longitudinal follow-up of cases
to estimate rates of diagnostic change. Based on the obtained sample size, with the alpha set
at .05, the study had 80% power to detect very small effect sizes (Cohen's d values of ≥.11
for t tests and Cohen's w values of ≥.065 for chi square tests).
Results
Preliminary analyses and sample characteristics
Complete information on the variables of interest for these analyses was available for 698 of
the 707 participants. Little's test indicated that the missing-completely-at-random
assumption was tenable. Because the assumption was tenable and the amount of missing
data was small (<2% on all relevant variables), we used listwise deletion. Therefore, the
number for all analyses was 698 unless otherwise indicated.
The LAMS sample has been previously described (1,7). Briefly, approximately two-thirds of
the 707 children were male (N=478, 68%) and white (N=455, 64%). Nearly half (N=323,
46%) were between the ages of six and eight. A total of 370 children (52%) were insured
solely through Medicaid. Primary diagnoses in the sample were bipolar disorders (N=162,
23%), depressive disorders (N=124, 18%), psychotic disorders (N=10, 1%), anxiety
disorders (N=43, 6%), disruptive behavioral disorders (N=212, 30%), ADHD (N=91, 13%),
and pervasive developmental disorders (N=28, 4%). A total of 433 children (61%) had mild
functional impairment, and 435 (62%) had taken psychotropic medications during their
lifetime. Eighteen youths were presenting for evaluation only and were not taking any
medication. As mentioned above, the youths without elevated symptoms of mania were less
likely than those with such symptoms to have a diagnosis of a bipolar disorder or a
disruptive behavior disorder; a larger proportion of the youths without elevated symptoms
had insurance other than Medicaid, but this difference was not significant. Otherwise, no
significant diagnostic or demographic differences were noted between the groups with and
without elevated symptoms of mania. Table 1 lists the demographic and clinical
characteristics of the study sample and presents data on bivariate associations by medication
group (no medications and one, two, or three or more medications).
A total of 201 of the 698 participants (29%) were prescribed two or more psychotropic
medications. LAMS participants receiving two or more medications had lower CGAS
scores, more comorbid disorders, and higher baseline P-GBI-10M, YMRS, and CDRS-R
scores than LAMS participants treated with no or one medication; the former group was also
were more likely to have a bipolar or pervasive developmental disorder, to have been placed
in special education, and to have been psychiatrically hospitalized, suggesting that children
who received two or more medications represented complex and difficult-to-treat cases. The
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proportion of males in the group taking three or more medications was significantly larger
than in the group taking no medications. In addition, the proportion of white youths in the
group taking two medications or three or more medications was significantly larger than in
the group taking no medications (all p<.05 based on post hoc comparisons). A larger
proportion of participants in the group taking no medication had Medicaid insurance, but the
difference was statistically significant only for the comparison with the group taking two
medications. Otherwise, no differences in demographic or insurance variables were found
between the children receiving two or more medications and those receiving no or one
medication.
Of the 262 participants who had not been prescribed any medications, 252 (96%) had one or
more diagnoses of a psychiatric disorder. The most common disorders reported for the 262
children included ADHD (67%), disruptive behavior disorders (56%), anxiety disorders
(36%), depressive disorder (21%), and elimination disorders (20%). Of the 262 children,
74% (N=194) had two or more psychiatric diagnoses. Children insured by Medicaid were
less likely to receive multiple medications for a psychiatric disorder than children not
insured by Medicaid. Post hoc sensitivity analyses found that 18 children (3% of the sample)
were seeking only evaluation and not treatment and were not taking medication. Excluding
these cases and rerunning the analyses did not change any of the estimates to two decimal
places.
Post hoc analyses found that participants treated with two or more medications were more
likely to be treated by a psychiatrist than by a pediatrician or a family practitioner (χ2=5.37,
df=1, p=.02). [A table listing the types of prescribing clinician for the groups taking one,
two, or three or more medications is available as on online data supplement to this article.]
Correlates of higher rates of polypharmacy
The finding that white youths were more rather than less likely to be prescribed two or more
medications was not consistent with some previous findings (6,22). Therefore, we conducted
a set of exploratory analyses to better characterize the robustness and nature of this finding.
First, we examined outlier diagnostics to determine whether any cases exerted undue effects
on the regression models. This was not the case. Second, we looked at bivariate associations
between white race and other variables to examine whether they followed expected patterns.
They did: with moderate unadjusted associations with site, point-biserial correlations
between white race and other variables ranged from –.40 (white youths less likely to be
insured by Medicaid,) to .25, for the total number of medications prescribed; .18 , for use of
antipsychotics; .15 , for antidepressants; .13, for anxiety diagnoses (that is, a larger
proportion of white participants with an anxiety diagnosis); .12, for mood stabilizers; .12, for
seeing a psychiatrist; .10, for pervasive developmental disorders; –.08, for disruptive
behavior disorders; –.08, for ADHD; .08, for seeing a psychologist; and .08, for overall
number of diagnoses (p,.05 for all rpb values; p,.005 for rpb greater than .11 or less than –.
11).
Finally, we conducted a set of logistic regressions exploring patterns of usage for the four
medication classes, evaluating which sets of predictors accounted for the most variance in
usage and also testing whether controlling for other demographic, clinical, and provider
characteristics reduced the higher odds of polypharmacy among white youths. Tables 2, 3,
and 4 summarize the results. Apparent site differences in the rates of antipsychotic, mood
stabilizer, and antidepressant use were no longer significant after adjustment for
demographic, clinical, and provider variables. No initial site differences in stimulant rates
were found. The block of demographic variables significantly predicted probability of usage
of all four medication classes; however, white race was the only demographic variable to
provide significant unique incremental information at all subsequent blocks of the models
Kowatch et al. Page 7













for antipsychotics, mood stabilizers, and antidepressants. Even when the analysis controlled
for all other variables, the odds of white youths receiving each of these three medication
classes were three times higher than for other youths with similar insurance, family histories,
diagnoses, severity of presentation, and access to professional providers. The white youths
were significantly more likely to have taken an antipsychotic in the past (r=.15, p<.001) and
a stimulant in the past (r=.13, p<.01) (Table 4 and Figure 1). After control for other
variables, no differences by race in current stimulant usage were found. Sensitivity analyses
found that excluding the 18 youths who were seeking only evalu ation and not taking
medication did not change the results.
Discussion
This study examined medication practice patterns in the carefully ascertained baseline
LAMS sample of 698 children with mood and behavior problems. The findings suggest
poly-pharmacy among just over one-fourth of children enrolled at their first outpatient child
mental health clinic visit. Among those who were receiving more than one medication, an
additional agent was often added to stimulant monotherapy for ADHD. Just over one-third
(38%) of participants were not treated with any psychotropic agents, even though most had
one or more psychiatric disorders. A substantial proportion of children with ADHD were not
receiving a stimulant or any other psychotropic treatment.
The finding that a majority of participants with bipolar disorder were treated with
antipsychotics, mood stabilizers, or both is consistent with practice patterns in other areas of
the country (23,24) and with current treatment guidelines for pediatric bipolar disorder (25).
Participants without bipolar disorder were treated mainly with stimulant medications. Unlike
other studies, this study found no evidence that minority race (26–28) or Medicaid status
(26) led to a greater likelihood of being prescribed psychotropic medications. Instead, the
odds of poly-pharmacy were three times higher among white youths than among non-white
youths, even after the analysis controlled for other demographic, insurance, and clinical
characteristics. This result contradicts some findings from prior claims-based studies (29)
but is similar to findings of clinical studies (22,30–33).
Our findings of increased psychiatric medication use among whites suggest that other
factors are at work. One possibility is differences in beliefs about the causes of mental
illness (34,35); another is differences in attitudes toward pharmacological treatment (36).
Other investigations have found that white middle-class families tend to subscribe more
often than other racial or ethnic groups to biological explanations of mental illness, and they
also tend to have more favorable attitudes toward medication as a component of treatment
(37,38). This study did not directly measure participants’ attitudes and beliefs; however, if
they were consistent with those of participants in previous studies, this would help explain
the robust difference in rates of polypharmacy observed in this study. A third possibility is
that white participants had more actively sought interventions (for example, from their
primary care physician) before arriving at the child mental health clinics from which they
were ascertained. This scenario is possible because the analyses indicated that white youths
in this sample were significantly more likely to have taken an antipsychotic or stimulant in
the past.
This study had several limitations. First, although 79% of eligible families agreed to
complete the screening instrument, only 56% of those eligible at screening agreed to
participate in the longitudinal portion of the study. Therefore, generalizability of these data
may be limited. Second, data on medication usage were based on parent report and were not
verified via another source, such as by monitoring prescription fills or by pill counts. Third,
because the sample included children who were experiencing elevated symptoms of mania,
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service utilization may be overestimated compared with general out-patient samples.
Finally, these data were cross-sectional, and reports of medication use are a mixture of
prescriptions before the mental health clinic visit and prescriptions by the mental health
clinic between screening and baseline assessment. However, results remained robust when
the analysis excluded participants who were seeking only evaluation and not taking
medication. Identification of patterns and predictors of service use and outcomes and
predictors of improved outcomes will require data from the longitudinal portion of the
LAMS study, which is currently in process.
Conclusions
These results contrast with findings from some studies of large pharmacoepidemiologic
claims–based data sets (6,39–41) that suggested that psychotropic medications are
overprescribed to children and adolescents. Results from pharmacoepidemiology studies are
often limited by selection bias, information bias, confounding, and lack of clear group
diagnostic validity and reliability (42,43). The LAMS study design complements claims-
based research by ascertaining a clearly defined group of cases and then using
semistructured diagnostic interviews to determine diagnoses and service utilization. In the
LAMS sample, when medications were prescribed, they appeared linked meaningfully to
diagnoses and functioning in ways broadly consistent with evidence-based practices and
with rational approaches to intervention in the community. The LAMS study is continuing
for a second five years, and in the near future we will be able to examine the effects of
psychiatric medication treatment— and nontreatment—on the clinical outcomes of youths in
this sample.
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Number of medications prescribed to white and nonwhite youths in the Longitudinal
Assessment of Manic Symptoms samplea
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Table 2
Predictors of polypharmacy among 698 participants in the Longitudinal Assessment of Manic Symptoms
a
Block df Nagelkerke R2 change p
Site 3 .04 <.001
Demographic characteristics 4 .07 <.001
Insurance and family history 3 .01 .241
Specific diagnoses 8 .09 <.001
Severity 4 .05 <.001
Provider type 3 .05 <.001
a
Based on logistic regressions predicting use of two or more medications concurrently. Sensitivity analyses using Poisson regression to predict the
count of the total number of medications found the same predictors and patterns, with slightly smaller p values for several due to the greater
variance in the dependent measure. Final model: Total R2=25, Nagelkerke R2 change=.30, p<.001
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Table 3
Incremental predictors of polypharmacy in the Longitudinal Assessment of Manic Symptoms
a
Predictor Change in odds p
White race 3.1 <.001
Attention-deficit hyperactivity disorder 2.5 .004
Bipolar disorders 1.8 .046
Psychiatric hospitalization 3.4 <.001
Being treated by a psychiatrist 2.3 <.001
Being treated by a psychologist 1.1 .011
Total professionals currently being seen 1.4 .009
a
df=1 for all predictors. Based on logistic regressions (final model) predicting use of two or more medications concurrently. Sensitivity analyses
using Poisson regression to predict the count of the total number of medications found the same predictors and patterns, with slightly smaller p
values for several due to the greater variance in the dependent measure.
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Table 4
Variance in prescription of medication class explained by demographic, clinical, and provider factors among
698 participants in the Longitudinal Assessment of Manic Symptoms
a
Nagelkerke R2 change





































Other medication classes 3 .01 .01 .00 <.01
a
Based on logistic regressions predicting use of respective medication class. White youths were significantly more likely to receive antipsychotics,
mood stabilizers, and antidepressants, and this difference remained significant at every subsequent block of the model. Final model total R2 (p<.
001 for all): antipsychotics, .40; mood stabilizers, .33; antidepressants, .26; and stimulants, .23. Change in odds of polypharmacy for white youths
in the final model: antipsychotics, 2.4 (95% confidence interval [CI]=1.3–4.2), p<.005; mood stabilizers, 2.5 (CI=1.0–6.2), p<.05; antidepressants,
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